Harvard Bioscience Announces the Successful Completion of Debt Refinancing with Comprehensive Growth Financing Package

Core Viewpoint - Harvard Bioscience, Inc. has entered into a $40 million credit facility agreement with BroadOak Capital Partners to refinance existing debt and strengthen its balance sheet [1][3] Financing Details - The credit facility consists of three term loans: Term Loan A and Term Loan B provide $32.5 million in gross proceeds, while Term Loan C is a $7.5 million convertible loan [2] - All loans mature on December 17, 2029, with quarterly principal amortization payments starting on December 31, 2027, for Term Loan A and Term Loan B [2] - BroadOak received warrants for 2 million shares at $0.50 per share and the right to nominate a board member [2] Strategic Importance - The financing package is seen as a significant milestone for the company, providing stability and flexibility for future operations [3] - The refinancing is expected to enhance liquidity and support the execution of strategic priorities [3] Board of Directors Update - Bill Snider from BroadOak has joined the board of directors and will serve on the compensation committee [4] - Snider brings over 30 years of investment experience in life sciences and has previously held significant roles in venture capital [4] Advisory Board Formation - A new Product, Operations, and Scientific Advisory Board will be established to guide commercial opportunities and product planning [5] Market Position and Future Outlook - Bill Snider expressed confidence in the company's position regarding new regulatory methodologies, indicating a strong future outlook [6]